167 related articles for article (PubMed ID: 33666154)
1. Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?
Campochiaro C; Tomelleri A; Galli E; Cocchiara E; Sartorelli S; Muratore F; Malattia C; Caorsi R; Catanoso MG; Baldissera E; Ravelli A; Salvarani C; Dagna L
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):129-134. PubMed ID: 33666154
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis.
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordström D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jørgensen TS; Jacobsson LTH; Askling J
J Rheumatol; 2021 Oct; 48(10):1512-1518. PubMed ID: 33649069
[TBL] [Abstract][Full Text] [Related]
3. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis.
Misra DP; Singh K; Rathore U; Patro P; Tomelleri A; Campochiaro C; Agarwal V; Sharma A
Autoimmun Rev; 2023 Mar; 22(3):103275. PubMed ID: 36652977
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
[TBL] [Abstract][Full Text] [Related]
6. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
7. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
9. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus.
Todoerti M; Favalli EG; Iannone F; Olivieri I; Benucci M; Cauli A; Mathieu A; Santo L; Minisola G; Lapadula G; Bucci R; Gremese E; Caporali R
Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii42-vii53. PubMed ID: 30289539
[TBL] [Abstract][Full Text] [Related]
10. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
11. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
Matsuno H; Katayama K
Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060
[TBL] [Abstract][Full Text] [Related]
14. The effects of biological agents on vascular structural lesions in Takayasu's arteritis.
Erbasan F; Uçar İ; Aslan B; Yazisiz V; Terzioğlu ME
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):135-141. PubMed ID: 33506752
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
16. Two cases of Takayasu's arteritis occurring under anti-TNF therapy.
Mariani N; So A; Aubry-Rozier B
Joint Bone Spine; 2013 Mar; 80(2):211-3. PubMed ID: 22999907
[TBL] [Abstract][Full Text] [Related]
17. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab.
Alibaz-Oner F; Kaymaz-Tahra S; Bayındır Ö; Yazici A; Ince B; Kalkan K; Kanıtez NA; Kocaer SB; Yasar Bilge NS; Omma A; Durak E; Ilgın C; Akar S; Kaşifoğlu T; Önen F; Emmungil H; İnanç M; Cefle A; Aksu K; Keser G; Direskeneli H
Semin Arthritis Rheum; 2021 Dec; 51(6):1224-1229. PubMed ID: 34706312
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Emery P; Gottenberg JE; Rubbert-Roth A; Sarzi-Puttini P; Choquette D; Taboada VM; Barile-Fabris L; Moots RJ; Ostor A; Andrianakos A; Gemmen E; Mpofu C; Chung C; Gylvin LH; Finckh A
Ann Rheum Dis; 2015 Jun; 74(6):979-84. PubMed ID: 24442884
[TBL] [Abstract][Full Text] [Related]
20. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]